Science Advances

The TurfMutt Foundation Shares 5 Reasons We Need More Yards, Parks and Community Green Space

Retrieved on: 
Montag, Mai 6, 2024
The Harris Poll, Sale, Mortality, Ecosystem, Nature, ASPCA, Pet, Risk, News, Science Advances, Health, Dream, Animal, Research, Insomnia, ADHD, USDA, Depression, CBS, Carbon, Life, Dementia, Heart rate, Plant, Schizophrenia, Attention, Violence, Tree, Oxygen, Email client, Erosion, DSM-IV codes, Butterfly, Bee, National Wildlife Federation, Newsletter, Anxiety, Asthma, Bird, Systematic review, Hunting

ALEXANDRIA, Va., May 6, 2024 /PRNewswire/ -- For 15 years the TurfMutt Foundation has advocated for the care and use of yards, parks, and other green spaces. These outdoor areas facilitate "backyarding," the act of taking every day activities that we normally do inside into the outdoor spaces around us such as dining, working, relaxing and more. This not only makes life more enjoyable, but it also improves the health and well-being of people pets and the planet.

Key Points: 
  • ALEXANDRIA, Va., May 6, 2024 /PRNewswire/ -- For 15 years the TurfMutt Foundation has advocated for the care and use of yards, parks, and other green spaces.
  • "Over the years, we've seen the benefits to families, communities and wildlife by having accessible green space to help balance our man-made environments," said TurfMutt CEO & President Kris Kiser.
  • Here are the top 5 reasons we need more managed green space in our backyards and communities:
    Plants, shrubs, trees, and grass are "environmental superheroes" that capture and filter rainwater, produce oxygen, and absorb carbon.
  • For more, sign up for Mutt Mail, a monthly e-newsletter with backyarding tips and all the news from the TurfMutt Foundation here .

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Dienstag, April 16, 2024
Pillar, Phase, Patient, Reperfusion, Kidney, Inflammation, Arch, Hospital, Randomness, OTCQB, Science Advances, IRI, TMX Group, Kidney disease, Research, Acute kidney injury, Ischemia, Yolo Bypass, Oxygen, Liver, User experience, Unity Health Toronto, Injury, Regeneration, Placebo-controlled study, AKI, Ethics, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no therapeutic treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Vagus nerve activation of the spleen shows promise to treat infections, Feinstein Institutes research

Retrieved on: 
Freitag, April 26, 2024
Biotechnology, Managed Care, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Hospitals, Science, Clinical Trials, Diamond, Autoantibody, Cancer, Bangladesh Technical Education Board, Inflammation, Biomedical engineering, National academy, National Academy of Sciences, Mouse, Crohn's disease, Pulmonary hypertension, Map, Science Advances, Vagus nerve stimulation, Inflammatory Bowel Diseases, Diabetes, Interface (computing), Neuroscience, Acetylcholine, Doctor of Philosophy, Spleen, VNS, DRS, Disease, Anatomy, Human, Sensation, Autoimmune disease, Nervous system, Arthritis, Molecular medicine, Physiology, Medicine, Immunology, Medical research, Multimedia, Lupus, Immune system, Antibody, Paralysis, Immunity, Credit, Autoimmunity, Sepsis, Vagus nerve, Vaccine

New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.

Key Points: 
  • New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.
  • This research highlights how the nervous system regulates immunity and suggests potential for non-pharmalogical, vagus nerve modulation to treat a variety of diseases, like lupus and sepsis.
  • Dr. Zanos’s research focus is on understanding the anatomy and physiology of the vagus nerve and the effects vagus nerve stimulation has in inflammation and cardiovascular diseases.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation

Retrieved on: 
Freitag, April 12, 2024
Leg, Brain, Inflammation, College of Engineering (KNUST), Post-traumatic stress disorder, Safety, Neuromodulation, Science Advances, Animal, Field line, Hand, Pathology, Depression, Tic disorder, Motor cortex, Mental health, Patient, Spinal cord, Miniature, DOT, DSM-IV codes, Transcranial magnetic stimulation, Digital, Manuscript, Rice University, TMS

HOUSTON, April 12, 2024 /PRNewswire/ -- Rice University today announced that Jacob Robinson, a professor of electrical and computer engineering and of bioengineering and founder and chief executive officer of Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health formed through the Rice Biotech Launch Pad, published a peer-reviewed study in Science Advances detailing a novel and wireless device - an epidural cortical stimulator known as the Digitally programmable Over-brain Therapeutic (DOT), that is capable of receiving enough energy to stimulate human and large-animal brain activity and can deliver bursts of electrical stimulation to the brain through the dura, the tough membrane that covers the brain and the spinal cord. The manuscript entitled "Miniature battery-free epidural cortical stimulators" can be viewed on the Science Advances website.

Key Points: 
  • The manuscript entitled " Miniature battery-free epidural cortical stimulators " can be viewed on the Science Advances website.
  • "However, current neuromodulation devices are either bulky, invasive, or limited in their stimulation capabilities.
  • It overcomes challenges by using a battery-free and wireless approach  to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery."
  • The study details how the DOT stimulator works by using magnetoelectric antennas that can convert magnetic fields into electric fields and vice versa.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Mittwoch, April 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Freitag, März 15, 2024
Libin Cardiovascular Institute, Kidney, User experience, Assistant, AKI, Patient, Kidney disease, Inflammation, Hospital, TMX Group, Acute kidney injury, University, Ischemia, Injury, Dispute board, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Division, Phase, OTCQB, Liver, Yolo Bypass, Randomness, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • “We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .

The ECB’s climate and nature plan 2024-2025

Retrieved on: 
Mittwoch, April 3, 2024
Civil service commission, SAFE, Communication, Temperature, Employment, Climate change, Growth, United Nations Environment Programme, Green, Environment, ECB, European Parliament, Agriculture, Blog, Risk, Green Deal, Climate, United Nations, Research, Policy, Food, Disclosure, Nature, Carbon, Flood, Commission, Biodiversity loss, Council, Science Advances, European, Investment, Tourism, Deutsche Bundesbank, Heart, Ecosystem, European Commission, Soil, Nickel, The Green Deal, European Environment Agency, Weather, Renewable energy

Climate change is increasingly affecting the euro area economy. That is why the ECB is committed to integrating climate change considerations into its activities. On 30 January 2024 the ECB published its climate and nature plan 2024-2025, which identifies three focus areas for its future work: (i) navigating the transition towards a green economy

Key Points: 


Climate change is increasingly affecting the euro area economy. That is why the ECB is committed to integrating climate change considerations into its activities. On 30 January 2024 the ECB published its climate and nature plan 2024-2025, which identifies three focus areas for its future work: (i) navigating the transition towards a green economy

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Donnerstag, März 7, 2024
Oxygen, Liver, OTCQB, CABG, User experience, Injury, Science Advances, Inflammation, Randomness, Hospital, Kidney disease, Acute kidney injury, National Research Council, TMX Group, Kidney, Yolo Bypass, IRI, Risk, Placebo-controlled study, Reperfusion, Prevalence, Arch, Ischemia, Disease, Patient, AKI, Phase, Mortality, Erciyes University, Faculty, Pharmaceutical industry

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Arch Biopartners team is currently working with hospital sites in Canada to prepare for their participation in this Phase II trial.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Dienstag, März 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Mittwoch, Januar 10, 2024
Mortality, Arch, Kidney, Patient, TMX Group, Ischemia, Reperfusion, Kidney disease, Oxygen, Yolo Bypass, Letter, Science Advances, AKI, Injury, Risk, CABG, OTCQB, Disease, Food, National Research Council, IRI, Acute kidney injury, Liver, Inflammation, Phase, Health Canada, Prevalence, Pharmaceutical industry

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.